Lynx1 Capital Management LP - 28 Oct 2025 Form 4 Insider Report for Cullinan Therapeutics, Inc. (CGEM)

Reporting relationship: 10%+ Owner
Issuer ticker: CGEM
Reported as of: 28 Oct 2025
Net transaction value: +$1,391,686
SEC form: 4
Accepted by SEC: 30 Oct 2025, 17:13:32 UTC
Prior SEC filing: 23 Oct 2025
Next SEC filing: 23 Dec 2025
Source filing: View source filing
Reporting owner signature: Lynx1 Capital Management LP, By: Lynx1 Capital Management GP LLC, its general partner, By: /s/ Weston Nichols, Sole Member

Key filing fact

Lynx1 Capital Management LP filed Form 4 for Cullinan Therapeutics, Inc. (CGEM) on 30 Oct 2025.

Key facts

This page summarizes Lynx1 Capital Management LP's Form 4 filing for Cullinan Therapeutics, Inc. (CGEM).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 30 Oct 2025, 17:13.

Change

Previous filing in this sequence was filed on 23 Oct 2025.
Current net transaction value: +$1,391,686.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (2)

CIK 0001910456 Primary reporting owner

Lynx1 Capital Management LP

Relationship: 10%+ Owner
Address: D81 CALLE C, SUITE 301 PMB 1202, DORADO, PUERTO RICO
Signature: Lynx1 Capital Management LP, By: Lynx1 Capital Management GP LLC, its general partner, By: /s/ Weston Nichols, Sole Member
Signature date: 30 Oct 2025

CIK 0001746376

Nichols Weston

Relationship: 10%+ Owner
Address: D81 CALLE C, SUITE 301 PMB 1202, DORADO, PUERTO RICO
Signature: /s/ Weston Nichols
Signature date: 30 Oct 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CGEM transaction

Common stock, $0.0001 par value per share

Purchase

Transaction value: $1,391,686
Shares: +165,667
Change %: +1.9%
Price: $8.40
Shares after: 8,963,500
Date: 28 Oct 2025
Ownership: See footnote
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.035 to $8.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

Footnote F2

The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any.